The Latin America, Middle East and Africa Apheresis Market would witness market growth of 11.1% CAGR during the forecast period (2022-2028).
A unit of whole blood is collected from a donor and sent to a research lab, where it is isolated into its four components such as red blood cells, white blood cells, platelets, and plasma – in traditional blood donation. The components are stashed and relying on the medical need are administered to patients following surgery, an accident, illness, or chemotherapy.
Whereas the donor is still attached to the separation device, apheresis separates the blood into these components. The donor's whole blood is separated into components based on density using a rotating centrifuge or a rotating belt.
The apheresis operator instructs the required component into a storage container using sterile equipment; the others return to the donor via a syringe inserted into a vein in the arm. In some cases, blood is collected and returned via a central line, which is an invasive procedure implanted into a vein in the upper shoulder.
The South African National Blood Service offers a hybrid therapeutic apheresis service that includes mobile and fixed-site apheresis, as well as an apheresis harvest of hematopoietic stem cells (HPC-A). Plasmapheresis, red cell exchange, and leukocyte and platelet reductions are among the therapeutic apheresis methods offered by SANBS. Additionally, apheresis is used to collect plasma, thrombocytes, mononuclear cells, including CD34+ cells (HPCs), and granulocytes for plasma and cellular therapies, as well as personalized apheresis products for research.
Since the 1970s, therapeutic plasma exchange has been utilised to treat immune-mediated illnesses. However, evidence outside the therapeutic indication is still anecdotal, relying on observed data and national registries from around the community. The original goal was to look at how therapeutic plasma exchange (TPE) was used to treat various illnesses in the Dubai Hospital's nephrology department and compare it to the American Society of Apheresis' (ASFA) standard indications categories.
The Brazil market dominated the LAMEA Apheresis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $84.4 million by 2028. The Argentina market is estimated to grow at a CAGR of 11.7% during (2022 - 2028). Additionally, The UAE market would witness a CAGR of 10.8% during (2022 - 2028).
Based on Procedure, the market is segmented into Donor/Automated and Therapeutic. Based on Product, the market is segmented into Disposable & Reagents, Devices, and Software. Based on Method, the market is segmented into Centrifugation, Membrane Separation, and Selective Adsorption. Based on End User, the market is segmented into Blood Centers, Hospitals, and Others. Based on Component, the market is segmented into Plasma (Plasmapheresis), Platelets (Plateletpheresis), Leukocytes (Leukapheresis or leukopheresis), Lymphocytes (Lymphopheresis or lymphapheresis), and RBC's (Erythropheresis). Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Apheresis Market is Predict to reach $4 Billion by 2028, at a CAGR of 8.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Asahi Kasei Medical Co., Ltd., Kaneka Corporation, Cerus Corporation, B. Braun Melsungen AG, Nikkiso Co., Ltd., Charles River Laboratories International, Inc., and SB Kawasumi Laboratories, Inc.
By Procedure
By Product
By Method
By End User
By Component
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 